Engineering Stable, Soluble, and Trimeric HIV gp140 by Paired Cys Scanning

Information

  • Research Project
  • 8507144
  • ApplicationId
    8507144
  • Core Project Number
    R43AI102626
  • Full Project Number
    5R43AI102626-02
  • Serial Number
    102626
  • FOA Number
    PA-10-123
  • Sub Project Id
  • Project Start Date
    7/6/2012 - 12 years ago
  • Project End Date
    6/30/2016 - 8 years ago
  • Program Officer Name
    LI, YEN
  • Budget Start Date
    7/1/2013 - 11 years ago
  • Budget End Date
    6/30/2016 - 8 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/24/2013 - 11 years ago
Organizations

Engineering Stable, Soluble, and Trimeric HIV gp140 by Paired Cys Scanning

DESCRIPTION (provided by applicant): When presented with a suitable antigenic Envelope (Env) structure, the human immune system can produce protective antibodies that HIV is unable to evade. Many of the most potently neutralizing HIV antibodies identified to date preferentially bind the trimeric structure of Env. Thus, recapitulating the native trimeric structure of Env as it exists on the virus and cell surface is a primary objective in developing an immunogen capable of generating broadly protective humoral immunity. The development of a soluble, trimeric Env structure that recapitulates the native, pre-fusion structure of Env has become a major goal for HIV vaccine advancement. However, the inherent instability of the gp120 and gp41subunit complex has posed a major obstacle in designing a soluble Env trimer (gp140) capable of presenting an effective antigenic structure to the immune system. The goal of this project is to engineer a gp140 variant with disulfide bonds that stabilize the trimer to yield conformationally intact, trimeric gp140. To accomplish the Aims of this project, we will engineer and test up to 10,000 gp140 variants that have been systematically mutated to contain paired disulfide bonds designed to covalently stabilize the protein. Each mutant will be individually expressed in human cells to maintain native post-translational processing, and each mutant will be tested for retention of its pre-fusion conformation, antigenic integrity, and trimeric structure.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    246301
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:246301\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    VACC
  • Study Section Name
    HIV/AIDS Vaccines Study Study Section
  • Organization Name
    INTEGRAL MOLECULAR
  • Organization Department
  • Organization DUNS
    034055645
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191045504
  • Organization District
    UNITED STATES